Sarda Proteins to Raise Up To ₹100 Crore Via Rights Issue

Sarda Proteins Limited's Board of Directors has given the green light for a rights issue aimed at raising up to ₹100 crore.

Reader Takeaway: Capital infusion via rights issue is positive; monitor issue terms and director changes for governance.

What just happened

The Board of Directors of Sarda Proteins Limited approved a rights issue of equity shares to eligible shareholders. The maximum fundraising target for this issuance is ₹100 crore (10,000 lakh). To facilitate this, a committee has been formed to oversee the rights issue process. The company also approved the Draft Letter of Offer for submission to SEBI and stock exchanges.

Separately, the company announced the resignation of Mr. Gunvantray Jayantilal Zaladi as a Non-Executive Director, effective August 5, 2026, citing personal reasons.

Why this matters

The rights issue signals Sarda Proteins' intention to secure additional capital, which could be used for expansion, debt repayment, or working capital needs. For existing shareholders, this presents an opportunity to increase their stake in the company, though it also means potential dilution if they do not participate. The formation of a dedicated committee indicates a structured approach to the fundraising.

The director's resignation, while attributed to personal reasons, is a governance event that shareholders watch for leadership stability.

The backstory

Sarda Proteins is involved in the manufacturing of protein products. Fundraising through rights issues is a common method for companies to raise capital from their existing shareholder base, allowing them to invest in growth or strengthen their financial position.

What changes now

The company will proceed with filing the Draft Letter of Offer with SEBI and stock exchanges. Shareholders will await further announcements detailing the record date, the rights entitlement ratio, and the issue price. The effective date of the director's resignation is August 5, 2026.

Risks to watch

Shareholders need to be aware of the potential dilution of their ownership if they do not subscribe to the rights issue. The terms of the rights issue, including the price and ratio, will be critical in determining its attractiveness. Any delays in SEBI approval or unforeseen market conditions could impact the fundraising.

Peer comparison

Details on peer fundraising activities were not provided in the filing.

Context metrics (time-bound)

• Fundraising Target: Up to ₹100 crore.
• Equity Share Face Value: ₹10.
• Director Resignation Effective Date: August 5, 2026.

What to track next

Investors should closely monitor Sarda Proteins' future announcements for the record date, the rights entitlement ratio, and the subscription period. Any updates on the utilization of the funds raised will also be important.